In the relentless fight against cancer, multidrug resistance (MDR) remains a significant hurdle, often rendering chemotherapy ineffective. One key player in this resistance is the Breast Cancer Resistance Protein (BCRP), also known as ABCG2, a transmembrane transporter that effluxes a wide range of cytotoxic drugs out of cancer cells. Understanding and overcoming the action of BCRP is crucial for improving patient outcomes. This is where compounds like YHO-13177 (CAS: 912287-56-0) come into play.

YHO-13177 has emerged as a valuable research chemical due to its potent and specific inhibitory activity against BCRP. Unlike some other inhibitors, YHO-13177 demonstrates a targeted effect, primarily interfering with BCRP-mediated drug transport without significantly impacting other efflux pumps like P-glycoprotein (P-gp). This specificity is vital for researchers aiming to dissect the precise role of BCRP in drug resistance. By blocking BCRP, YHO-13177 can effectively re-sensitize cancer cells that have become resistant to therapies like SN-38, mitoxantrone, and topotecan.

The ability of YHO-13177 to potentiate the cytotoxicity of these agents in cell lines engineered to overexpress BCRP, while having minimal effect on parental cell lines or those resistant to other mechanisms, underscores its utility in YHO-13177 BCRP inhibitor mechanisms studies. Researchers utilize YHO-13177 to validate BCRP's contribution to drug resistance and to screen for new therapeutic agents that can either inhibit BCRP or work synergistically with existing chemotherapy. The availability of YHO-13177 from reputable YHO-13177 supplier China and other global sources ensures that scientific investigation can proceed with reliable and high-quality materials.

The implications of YHO-13177 extend to the development of novel cancer therapies. By understanding how BCRP contributes to resistance and how compounds like YHO-13177 can counteract it, pharmaceutical companies can design more effective treatment regimens. This includes exploring combination therapies where YHO-13177 might be co-administered with chemotherapy to improve response rates in patients whose tumors exhibit high BCRP expression. The ongoing research into YHO-13177 supports the broader goal of advancing cancer therapy research by providing crucial insights into overcoming cellular defense mechanisms.

For scientists in the field of oncology and drug discovery, obtaining high-purity YHO-13177 is paramount. Reliable suppliers ensure that the compound meets stringent quality standards, critical for reproducible experimental results. The strategic use of YHO-13177 as a research tool is paving the way for a deeper understanding of drug resistance and the potential development of more successful cancer treatments.